Monitor upcoming quarterly reports for signs of revenue growth from the Hyloris licensing deal and the Talicia joint venture, as the current financials show declining fundamentals despite positive balance sheet improvements. The company's ability to generate revenue from its pipeline will be critical to justifying the current market valuation.
Price Chart
Executive Summary
RedHill Biopharma reported its 2025 financial results, highlighting a strategic transformation through partnerships with Cumberland Pharmaceuticals and Hyloris, which unlocked $60 million in potential milestone payments. The company's Talicia business was restructured into a joint venture, improving the balance sheet and ending the year with positive equity of $4.3 million, up from a $4.7 million capital deficiency in 2024. However, revenue from continuing operations declined significantly, and the company reported a net loss from continuing operations of $8.1 million.
Key Facts
- Revenue from continuing operations was $0.3 million in 2025, up from $0 in 2024, but down significantly from prior years due to the Talicia business being classified as discontinued operations
- Net loss from continuing operations was $8.1 million in 2025, compared to net income of $0.4 million in 2024
- Formed Talicia Holdings Inc. joint venture with Cumberland Pharmaceuticals, receiving $4 million investment for 30% equity stake
- Licensed RHB-102 (Bekinda) to Hyloris for up to $60 million in potential milestone payments plus royalties
- Ended 2025 with positive equity of $4.3 million, compared to a capital deficiency of $4.7 million at year-end 2024
- Cash balance was $4.1 million as of December 31, 2025
Financial Impact
Revenue from continuing operations declined to $0.3 million, net loss from continuing operations increased to $8.1 million, but balance sheet improved with positive equity of $4.3 million
Risk Factors
- Revenue from continuing operations remains minimal at $0.3 million
- Net loss from continuing operations increased significantly to $8.1 million
- Future milestone payments from partnerships are uncertain and not guaranteed
- Heavy reliance on pipeline development with no near-term revenue visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002231 |
| Document: 0001178913-26-002231-index-headers.html | 0001178913-26-002231 |
| Document: 0001178913-26-002231-index.html | 0001178913-26-002231 |
| Document: 0001178913-26-002231.txt | 0001178913-26-002231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers